PMID- 33106565
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Oct 26
TI  - Quantitative analysis of choroidal vasculature in polypoidal choroidal 
      vasculopathy using ultra-widefield indocyanine green angiography.
PG  - 18272
LID - 10.1038/s41598-020-75506-7 [doi]
LID - 18272
AB  - Polypoidal choroidal vasculopathy (PCV) is a common choroidal vascular disease 
      particularly in Asians. However, the underlying pathogenesis of PCV is still yet 
      to be fully elucidated, and the correlation between choroidal vasculature and 
      treatment response of PCV are poorly understood. Accordingly, we sought to find 
      clues to understand the pathogenesis and prognosis of PCV by quantitatively 
      evaluating choroidal vasculature from the entire fundus using ultra-widefield 
      (UWF) indocyanine green angiography (ICGA). In this study, 32 eyes from 29 
      patients with treatment naive PCV and 30 eyes from 30 healthy control 
      participants were enrolled. Choroidal vascular density (CVD) of PCV eyes was 
      higher than normal eyes in majority regions including the periphery. CVD was 
      positively correlated with choroidal thickness and choroidal hyperpermeability, 
      supporting that the pathogenesis of PCV may include choroidal congestion and 
      dilatation. Thicker choroid and higher CVD were also correlated with poor 
      treatment response after anti-VEGF injections. The CVD, quantified from UWF ICGA 
      can also be used as an effective image biomarker to predict the treatment 
      response in PCV.
FAU - Ryu, Gahyung
AU  - Ryu G
AD  - Department of Ophthalmology, Yeungnam University College of Medicine, #170 
      Hyunchungro, Nam-gu, Daegu, 42415, South Korea.
AD  - Yeungnam Eye Center, Yeungnam University Hospital, Daegu, South Korea.
FAU - Moon, Cheolwon
AU  - Moon C
AD  - Department of Ophthalmology, Yeungnam University College of Medicine, #170 
      Hyunchungro, Nam-gu, Daegu, 42415, South Korea.
AD  - Yeungnam Eye Center, Yeungnam University Hospital, Daegu, South Korea.
FAU - van Hemert, Jano
AU  - van Hemert J
AD  - Optos PLC, Dunfermline, UK.
FAU - Sagong, Min
AU  - Sagong M
AD  - Department of Ophthalmology, Yeungnam University College of Medicine, #170 
      Hyunchungro, Nam-gu, Daegu, 42415, South Korea. msagong@ynu.ac.kr.
AD  - Yeungnam Eye Center, Yeungnam University Hospital, Daegu, South Korea. 
      msagong@ynu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - IX6J1063HV (Indocyanine Green)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Bevacizumab/therapeutic use
MH  - Case-Control Studies
MH  - Choroid Diseases/*diagnosis/drug therapy
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Indocyanine Green/*administration & dosage
MH  - Macular Degeneration/*diagnosis/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Ranibizumab/therapeutic use
MH  - Receptors, Vascular Endothelial Growth Factor/therapeutic use
MH  - Recombinant Fusion Proteins/therapeutic use
MH  - Treatment Outcome
PMC - PMC7589486
COIS- The authors declare no competing interests.
EDAT- 2020/10/28 06:00
MHDA- 2020/12/22 06:00
PMCR- 2020/10/26
CRDT- 2020/10/27 05:44
PHST- 2020/06/23 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/27 05:44 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/10/26 00:00 [pmc-release]
AID - 10.1038/s41598-020-75506-7 [pii]
AID - 75506 [pii]
AID - 10.1038/s41598-020-75506-7 [doi]
PST - epublish
SO  - Sci Rep. 2020 Oct 26;10(1):18272. doi: 10.1038/s41598-020-75506-7.